Drug Trial Radar · NCT07059845
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Nov 13, 2025
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. In substudy 3, arms F and G, participants will receive one of two doses of MIRV with BEV and carboplatin, followed by MIRV with BEV. Approximately 400 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused carboplatin and Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Conditions
- Ovarian Cancer
Interventions
Mirvetuximab SoravtansineDrug
Intravenous (IV) infusion
BevacizumabDrug
IV Infusion
CarboplatinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3)Time frame: Up to Approximately 40 Months
- Substudy 1, 2, and 3: Number of Participants with TEAEs Leading to DiscontinuationTime frame: Up to Approximately 40 Months
- Substudy 1, 2, and 3: Number of Participants with Ocular Adverse Events (AEs) (any grade, Grade >= 2)Time frame: Up to Approximately 40 Months
- Substudy 1, 2, and 3: Overall Response (OR) as Assessed by the Investigator per RECIST v1.1Time frame: Up to Approximately 40 Months
- Substudy 1: Progression free survival (PFS) as Assessed by the Investigator per RECIST v1.1Time frame: Up to Approximately 40 Months
Locations
86 sites in 8 countries. Site status is shown where the registry gives one.
UC San Diego Health - Moores Cancer Center /ID# 277574
La Jolla, California · Recruiting
Sansum Clinic - Solvang /ID# 277712
Solvang, California · Active not recruiting
University of Florida College of Medicine /ID# 278348
Gainesville, Florida · Recruiting
Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623
Orlando, Florida · Recruiting
Florida Cancer Specialists - North /ID# 278626
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists - East /ID# 278605
West Palm Beach, Florida · Recruiting
Baptist Health Lexington /ID# 278267
Lexington, Kentucky · Recruiting
Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440
Baton Rouge, Louisiana · Recruiting
Maine Medical Center - Scarborough Campus /ID# 277205
Scarborough, Maine · Recruiting
UMass Memorial Medical Center - Belmont Street /ID# 278628
Worcester, Massachusetts · Recruiting
Karmanos Cancer Institute - Detroit /ID# 277085
Detroit, Michigan · Recruiting
Intermountain Health - Intermountain Health West End Clinic /ID# 278470
Billings, Montana · Recruiting
Md Anderson Cancer Center At Cooper /ID# 278390
Camden, New Jersey · Recruiting
Columbia University Medical Center /ID# 277990
New York, New York · Recruiting
SUNY Upstate Medical University - Syracuse /ID# 277245
Syracuse, New York · Recruiting
FirstHealth of the Carolinas- Speciality Center /ID# 278636
Pinehurst, North Carolina · Recruiting
Jamescare Gynecologic Oncology At Mill Run /ID# 277951
Hilliard, Ohio · Recruiting
Willamette Valley Cancer Institute and Research Center /ID# 277714
Eugene, Oregon · Recruiting
Penn Medicine University of Pennsylvania Health System /ID# 277963
Philadelphia, Pennsylvania · Recruiting
Western Pennsylvania Gynecologic Oncology /ID# 278632
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute - Sioux Falls /ID# 278627
Sioux Falls, South Dakota · Recruiting
University Of Tennessee Medical Center /ID# 278225
Knoxville, Tennessee · Recruiting
Texas Oncology - Abilene - Antilley Road /ID# 277739
Abilene, Texas · Recruiting
University of Texas - Southwestern Medical Center /ID# 278289
Dallas, Texas · Recruiting
Texas Oncology - Fort Worth Cancer Center /ID# 277989
Fort Worth, Texas · Recruiting
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735
San Antonio, Texas · Recruiting
Texas Oncology - The Woodlands /ID# 277926
The Woodlands, Texas · Recruiting
Texas Oncology - Northeast Texas /ID# 277737
Tyler, Texas · Recruiting
Virginia Commonwealth University Medical Center /ID# 277932
Richmond, Virginia · Recruiting
Virginia Mason Hospital and Medical Center /ID# 277259
Seattle, Washington · Recruiting
West Virginia University Hospitals /ID# 278965
Morgantown, West Virginia · Recruiting
St. George Private Hospital /ID# 276570
Kogarah, New South Wales, Australia · Recruiting
Chris O'Brien Lifehouse /ID# 276337
Sydney, New South Wales, Australia · Recruiting
Icon Cancer Centre Wesley /ID# 277199
Auchenflower, Queensland, Australia · Recruiting
Burnside War Memorial Hospital /ID# 277602
Adelaide, South Australia, Australia · Recruiting
Icon Cancer Centre Hobart /ID# 277688
Hobart, Tasmania, Australia · Recruiting
Monash Health - Monash Medical Centre - Clayton /ID# 276984
Clayton, Victoria, Australia · Recruiting
Barwon Health /ID# 277297
Geelong, Victoria, Australia · Recruiting
Austin Hospital /ID# 276534
Melbourne, Victoria, Australia · Recruiting
Epworth HealthCare /ID# 276347
Richmond, Victoria, Australia · Recruiting
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.